BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149

· BGB149 is the first therapeutic anti-AXL monoclonal antibody to enter clinical development · BGB149 is BerGenBio’s second novel clinical candidate targeting AXL · Phase I study will investigate safety and pharmacokinetics in healthy volunteersBergen, Norway, January 9 2019 - BerGenBio ASA (OSE:BGBIO),a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting AXL kinase to treat aggressive diseases including immune-evasive and therapy resistant cancers, announces today that the first subject has been dosed in a Phase I